ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Gramm-Rudman-Hollings Could Slash NCI Budget By $650 Million; Holleb Retires From ‘Ca’

July 27, 1990

Hammer Agrees To Bush Request for FDA Probe

July 15, 1988

FASEB Urges Congress To Fund Stem Cell Research.

July 27, 2001

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

January 22, 1993

NCCS Networker Volume 4 Issue 3, Summer 1990

June 13, 1990

In Brief: President’s Request For NCI FY 1981 Budget: Same As 1980; New Clinical Study Section Option Open

December 14, 1979